Clinical Trials Logo

Filter by:
NCT ID: NCT05824871 Enrolling by invitation - Clinical trials for Rifampicin-resistant Tuberculosis

Sudapyridine (WX-081) in RR/MDR/XDR-tuberculosis Patients

WISH
Start date: September 2, 2022
Phase: Phase 3
Study type: Interventional

The objective of this study is to demonstrate that the antibacterial activity of Sudapyridine (WX-081) is not inferior to Bedaquiline when added to a Background Regimen (BR) for treatment of rifampicin- resistant TB. Also, safety and clinical outcome will be evaluated.

NCT ID: NCT05824520 Not yet recruiting - Clinical trials for Coronary Artery Disease

Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy

ACCURATE II
Start date: May 4, 2023
Phase: N/A
Study type: Interventional

The overall purpose of ACCURATE II trial is to compare the clinical outcomes of CT-derived FFR guided strategy versus medical therapy in patients with chronic coronary syndrome.

NCT ID: NCT05824481 Not yet recruiting - Endometrial Cancer Clinical Trials

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with lenvatinib in patients with advanced endometrial cancer. The primary objective is to evaluate objective response rate of cadonilimab plus lenvatinib.

NCT ID: NCT05824468 Not yet recruiting - Cervical Cancer Clinical Trials

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

Although immune checkpoint inhibitors (ICIs) provide a durable response in multiple tumor types, relapse occurs in most patients with solid tumor. However, the benefits of retreatment with ICIs remains controversial. In some studies, retreatment with ICIs has exhibited encouraging efficacy in patients with solid tumors, particularly in melanoma, and non-small cell lung cancer (NSCLC). In this single arm phase 2 trial, we aimed to evaluate the efficacy and safety of the combination of anti-PD1 antibody (zimberelimab) and lenvatinib in patients with advanced cervical cancer who progressed on or after prior ICIs.

NCT ID: NCT05824455 Recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors

Start date: March 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The Phase Ib study was designed to evaluate the safety of JS109 in combination with irinotecan in the treatment of advanced solid tumors and to determine the Phase II recommended dose (RP2D). The Phase II study was designed to evaluate the efficacy and safety of the combination regimen in patients with extensive small-cell lung cancer (SCLC) that failed first-line platinum-containing regimen.

NCT ID: NCT05824390 Active, not recruiting - IgA Nephropathy Clinical Trials

A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

Start date: June 20, 2020
Phase: Phase 4
Study type: Interventional

A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.

NCT ID: NCT05824325 Active, not recruiting - Breast Cancer Clinical Trials

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer(GALAXY)

Start date: March 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phaseⅠb/Ⅱ, open-label, two-arm parallel study evaluating the efficacy and safety of different targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer

NCT ID: NCT05824312 Recruiting - Thyroid Cancer Clinical Trials

HRQOL in Locally Advanced Thyroid Carcinoma

LATCQOL
Start date: February 1, 2023
Phase:
Study type: Observational

The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).

NCT ID: NCT05824299 Not yet recruiting - Bladder Cancer Clinical Trials

Influence of Anesthesia Methods on CTCs in TURBT Patients

Start date: August 15, 2023
Phase: N/A
Study type: Interventional

Multiple lines of evidence have shown that anesthesia method is associated with long-term outcomes in patients undergoing surgery due to cancers, including lung, breast, prostate, and bladder cancer, etc. Circulating tumor cells (CTCs) have been validated as prognostic biomarkers of a number of cancers. The aim of this study is to investigate the effects of anesthesia methods on the number of CTCs in patients receiving transurethral resection of bladder tumor (TURBT). The difference of anesthesia method is achieved by using general anesthesia in one group and spinal anesthesia in the other group.

NCT ID: NCT05824286 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

HbA1c Prediction Model in Patients With Type 2 Diabetes

Start date: January 4, 2023
Phase: N/A
Study type: Interventional

Patients with type 2 diabetes who have poor blood glucose control are enrolled to evaluate the efficacy and safety of the HbA1c prediction model for adjust the hypoglycemic treatment regimen, compared with the conventional treatment using self-monitoring blood glucose or glycated albumin.